• N. Engl. J. Med. · May 2019

    Randomized Controlled Trial Multicenter Study

    Antibacterial Envelope to Prevent Cardiac Implantable Device Infection.

    • Khaldoun G Tarakji, Suneet Mittal, Charles Kennergren, Ralph Corey, Jeanne E Poole, Edward Schloss, Jose Gallastegui, Robert A Pickett, Rudolph Evonich, François Philippon, Janet M McComb, Steven F Roark, Denise Sorrentino, Darius Sholevar, Edmond Cronin, Brett Berman, David Riggio, Mauro Biffi, Hafiza Khan, Marc T Silver, Jack Collier, Zayd Eldadah, David J Wright, Jeff D Lande, Daniel R Lexcen, Alan Cheng, Bruce L Wilkoff, and WRAP-IT Investigators.
    • From the Cleveland Clinic, Cleveland (K.G.T., B.L.W.), and the Lindner Research Center, Cincinnati (E.S.) - both in Ohio; Valley Health System, Ridgewood (S.M.), and Lourdes Cardiology Services, Cherry Hill (D. Sholevar) - both in New Jersey; Sahlgrenska University Hospital, Göteborg, Sweden (C.K.); Duke Clinical Research Institute, Durham (R.C.), and WakeMed Heart and Vascular, WakeMed Health and Hospitals, Raleigh (M.T.S.) - both in North Carolina; University of Washington School of Medicine, Seattle (J.E.P.); Clearwater Cardiovascular and Interventional Consultants, Safety Harbor (J.G.), and Cardiology Associates of Gainesville, Gainesville (S.F.R.) - both in Florida; Saint Thomas Research Institute, Nashville (R.A.P.); Upper Michigan Cardiovascular Associates, Marquette (R.E.); Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC, Canada (F.P.); the Newcastle upon Tyne Hospitals, Newcastle upon Tyne (J.M.M.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom; Iowa Heart Center, West Des Moines (D. Sorrentino); Hartford Hospital, Hartford, CT (E.C.); Chula Vista Cardiac Center, Chula Vista, CA (B.B.); Arizona Arrhythmia Consultants, Scottsdale (D.R.); Policlinico Sant' Orsola-Malpighi, Bologna, Italy (M.B.); Baylor Research Institute, Plano, TX (H.K.); Oklahoma Heart Hospital, Oklahoma City (J.C.); MedStar Heart and Vascular Institute, Washington, DC (Z.E.); and Medtronic, Mounds View, MN (J.D.L., D.R.L., A.C.).
    • N. Engl. J. Med. 2019 May 16; 380 (20): 1895-1905.

    BackgroundInfections after placement of cardiac implantable electronic devices (CIEDs) are associated with substantial morbidity and mortality. There is limited evidence on prophylactic strategies, other than the use of preoperative antibiotics, to prevent such infections.MethodsWe conducted a randomized, controlled clinical trial to assess the safety and efficacy of an absorbable, antibiotic-eluting envelope in reducing the incidence of infection associated with CIED implantations. Patients who were undergoing a CIED pocket revision, generator replacement, or system upgrade or an initial implantation of a cardiac resynchronization therapy defibrillator were randomly assigned, in a 1:1 ratio, to receive the envelope or not. Standard-of-care strategies to prevent infection were used in all patients. The primary end point was infection resulting in system extraction or revision, long-term antibiotic therapy with infection recurrence, or death, within 12 months after the CIED implantation procedure. The secondary end point for safety was procedure-related or system-related complications within 12 months.ResultsA total of 6983 patients underwent randomization: 3495 to the envelope group and 3488 to the control group. The primary end point occurred in 25 patients in the envelope group and 42 patients in the control group (12-month Kaplan-Meier estimated event rate, 0.7% and 1.2%, respectively; hazard ratio, 0.60; 95% confidence interval [CI], 0.36 to 0.98; P = 0.04). The safety end point occurred in 201 patients in the envelope group and 236 patients in the control group (12-month Kaplan-Meier estimated event rate, 6.0% and 6.9%, respectively; hazard ratio, 0.87; 95% CI, 0.72 to 1.06; P<0.001 for noninferiority). The mean (±SD) duration of follow-up was 20.7±8.5 months. Major CIED-related infections through the entire follow-up period occurred in 32 patients in the envelope group and 51 patients in the control group (hazard ratio, 0.63; 95% CI, 0.40 to 0.98).ConclusionsAdjunctive use of an antibacterial envelope resulted in a significantly lower incidence of major CIED infections than standard-of-care infection-prevention strategies alone, without a higher incidence of complications. (Funded by Medtronic; WRAP-IT ClinicalTrials.gov number, NCT02277990.).Copyright © 2019 Massachusetts Medical Society.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,624,503 articles already indexed!

We guarantee your privacy. Your email address will not be shared.